Brief: Astrazeneca Reports Favourable Safety Profile For Efzimfotase Alfa In Phase III HPP Trials
28/06/2026 20:53
BRIEF-Astrazeneca Reports Favourable Safety Profile For Efzimfotase Alfa In Phase III HPP Trials June 28 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA - REPORTS FAVOURABLE SAFETY PROFILE FOR EFZIMFOTASE ALFA IN PHASE III HPP TRIALS
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains